Results 131 to 140 of about 32,846 (250)

Diabetes management in people undergoing metabolic‐bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) Group

Diabetic Medicine, EarlyView.
Abstract The global prevalence of obesity and diabetes continues to rise, with metabolic‐bariatric surgery recognised as an effective intervention for obesity and type 2 diabetes, offering potential for type 2 diabetes remission and improved glycaemic control. This guideline, developed by the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP)
Jeffrey W. Stephens, Ketan Dhatariya, Andrew J. Beamish, Dimitri J. Pournaras, Alexander D. Miras, Nader Raafat, Georgia Noble‐Bell, Rachel Cadwallader Buckland, Omar G. Mustafa   +8 more
wiley   +1 more source

Real‐world treatment trajectories preceding GLP‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
Franziska S. Ulrich, Morten Frost Nielsen, Nicola Napoli, Andrea M. Burden   +3 more
wiley   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

Uptake and early outcomes of a meal replacement intervention in an ethnically diverse adult population living with obesity and significant comorbidity

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Structured meal replacement low energy diets (MR‐LED) are effective in obesity management, but evidence for individuals of minority ethnic groups or those with BMI >35 kg/m2 and significant comorbidities is limited. Materials and methods We evaluated the early effectiveness of a weight management program delivered by a multidisciplinary ...
James Shand, Naomi Brosnahan, Yannan Jiang, Rinki Murphy   +3 more
wiley   +1 more source

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain. Aim To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4
Kathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Hannah Karin Wood‐Kurland, Ulrik Pedersen‐Bjergaard, Mikkel Porsborg Andersen, Jens Michelsen, Henrik Imberg, Marcus Lind, Sara Hallström, Stefanie Lanzinger, Anders Munch, Johan Sebastian Ohlendorff, Thomas Alexander Gerds, Christian Torp‐Pedersen, The REDDIE Consortium   +15 more
wiley   +1 more source

Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Renal microvascular dysfunction is a central driver of diabetic kidney disease, yet the potential for rapid therapeutic reversal remains obscure. We investigated the effect of short‐term liraglutide on early changes in the renal microcirculation post‐induction of diabetes.
Yuan Li, Weiqi Liu, Yingyu Wang, Bing Wang, Xiang Xu, Bingwei Li, Mingming Liu, Xu Zhang, Ruijuan Xiu   +8 more
wiley   +1 more source

GLP‐1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background The escalating use of Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is reshaping pharmaceutical consumption patterns and posing unprecedented challenges to healthcare systems worldwide. This study analyzes the landscape of GLP‐1 RA consumption, safety monitoring and regulatory oversight in Brazil.
Renato Lopes Hurtado, Angélica Amorim Amato, Hugo de Luca Corrêa, Dâmaris Silveira   +3 more
wiley   +1 more source

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

International Journal of Nanomedicine, 2017
Quan Qi,1,* Lei Lu,2,3,* Haiqing Li,1,* Zhize Yuan,1 Gaoxian Chen,2,3 Miao Lin,2,3 Zhengwen Ruan,4 Xiaofeng Ye,1 Zeyu Xiao,2,3,5 Qiang Zhao1 1Department of Cardiac Surgery, Rui Jin Hospital, 2Department of Pharmacology, Institute of Medical Sciences ...
Qi Q, Lu L, Li H, Yuan Z, Chen G, Lin M, Ruan Z, Ye X, Xiao Z, Zhao Q   +9 more
doaj  

Actualización y puesta al día en diabetes mellitus tipo II [PDF]

, 2014
53 páginasCurso de Experto Universitario en Medicina de Urgencias y Emergencias (2013). Director: Manuel García del Río. La diabetes mellitus (DM) es una enfermedad crónica que requiere una continua atención médica y autogestión por parte del paciente ...
Jiménez Rodríguez, Irene
core  

Dose‐Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims/Hypothesis Initial dose‐escalation has been shown to mitigate gastrointestinal adverse events in people treated with incretin‐based medications. We aimed to analyse dose‐response relationships for the proportion of study participants reporting nausea and vomiting among those exposed to incretin mimetics approved for Type 2 diabetes (GLP‐1
Michael A. Nauck, Viktoria Punov, Yu Mi Kang, Soo Lim   +3 more
wiley   +1 more source